Evidence map›Paper›PMID 41394641›Full record

ArticlebioRxiv : the preprint server for biology2025

Neuronal APOE4 alone is sufficient to drive tau pathology, neurodegeneration, and neuroinflammation in an Alzheimer's disease mouse model.

Jessica Blumenfeld, Yaqiao Li, Min Joo Kim, Oscar Yip, Luokang Yao, Samuel De Leon, Rebecca Fulthorpe, David Shostak, Zoe Platow, Kaylie Suan and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jessica BlumenfeldGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-5470-6901
Yaqiao LiGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-9433-7346
Min Joo KimGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-7906-0115
Oscar YipGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0001-9096-7167
Luokang YaoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Samuel De LeonGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Rebecca FulthorpeGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-3232-5665
David ShostakGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-1768-6374
Zoe PlatowGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0009-0004-9804-7049
Kaylie SuanGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Yanxia HaoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Nicole KoutsodendrisGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-2761-1480
Claire EllisGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Jeremy NguyenGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Yadong HuangGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-5871-4589

Funding

Project 4: Cross-species Dissection of Cellular Response to APOE Genotype and AD Pathology Using Single-cell Multi-omicsP01AG073082 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG, MUCKE, LENNART · 2021 to 2025
$23.4M
Neuronal ApoE Drives Selective Neurodegeneration in Alzheimer's DiseaseR01AG071697 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG · 2021 to 2025
$4.1M
Study Susceptibility and Resistance to ApoE4 in Alzheimer's DiseaseRF1AG076647 · NIA · J. DAVID GLADSTONE INSTITUTES · PI HUANG, YADONG · 2022 to 2022
$2.6M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
NIA NIH HHS P01 AG073082NIA NIH HHS R01 AG071697NIA NIH HHS RF1 AG076647NIH HHS S10 OD028511
6 · The paper itself

Abstract

Apolipoprotein E4 (APOE4), the strongest genetic risk factor for late-onset Alzheimer's disease (AD), exacerbates tau tangles, amyloid plaques, neurodegeneration, and neuroinflammation-the pathological hallmarks of AD. While astrocytes are the primary producers of APOE in the CNS, neurons increase APOE expression under stress and aging. Prior work established that neuronal APOE4 is essential for AD pathogenesis, but whether it is sufficient to drive disease remained unknown. We generated a PS19 tauopathy mouse model selectively expressing APOE4 in neurons. Neuronal APOE4 alone proved sufficient to promote pathological tau accumulation and propagation, neurodegeneration, and neuroinflammation to levels comparable to a tauopathy model with human APOE4 knocked-in globally. Single-nucleus RNA sequencing further revealed similar transcriptomic changes in neurons and glia of both models. Together, these findings demonstrate that neuronal APOE4 alone can initiate and propagate AD pathologies, underscoring its pivotal role in disease pathogenesis and its potential as a therapeutic target.

Identifiers

PMID41394641
PMCPMC12697731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.